[{"uuid": "2ed89aa2-c705-3d7c-94d6-bb08e29126e8", "title": "Ellen Bower Joins Parallel ENT & Allergy as CEO", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/ellen-bower-joins-parallel-ent-140000781.html", "providerPublishTime": 1738591200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MYGhBkOsMH9X9IhA72JuAw--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/770a98b050e625589559a6fb26c6a4b6", "width": 400, "height": 98, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/TPcTGTP.FUFdVMDnWOn.kw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/770a98b050e625589559a6fb26c6a4b6", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "57ad34d9-32fc-3b5f-bc32-c8be627eadb4", "title": "50 years on, Umm Kulthum is still the voice of the Arab world", "publisher": "AFP", "link": "https://finance.yahoo.com/m/57ad34d9-32fc-3b5f-bc32-c8be627eadb4/50-years-on%2C-umm-kulthum-is.html", "providerPublishTime": 1738379685, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/f96Lr75y6Dett0dx0EmR1A--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/afp.com/e35fb337c071cee110e0ab76f21dc901", "width": 768, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/UuuXfvMsMchiCe73Q5O5rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/afp.com/e35fb337c071cee110e0ab76f21dc901", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "0d6cdfc3-7c42-3c95-9a2d-dcf7e61f8708", "title": "Shionogi\u2019s RSV antiviral reduces viral load in Phase II human challenge trial", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/0d6cdfc3-7c42-3c95-9a2d-dcf7e61f8708/shionogi%E2%80%99s-rsv-antiviral.html", "providerPublishTime": 1738242211, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/9Hf9TC8wUs6iN3AXv59HWg--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/d61a4a2ff8c5b5f7469ee10bc64dae48", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/mLjuAWBD6dfND61PnEB6xw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/d61a4a2ff8c5b5f7469ee10bc64dae48", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA", "MRNA"]}, {"uuid": "ef34416d-6d63-373c-b07f-ee5a8600e39a", "title": "Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-moves-8-144500353.html", "providerPublishTime": 1737643500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/k4qFrd7eQZOz7UPW3QhYfg--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f3f6997d2f959f9932a4b5651829a773", "width": 900, "height": 625, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1Bnge8iOH3KgXEZLsgau9g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/f3f6997d2f959f9932a4b5651829a773", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["RXRX", "ENTA"]}, {"uuid": "e08d4e49-4dfd-32dd-83c5-b0cf3577c89d", "title": "Veteran Allergist and Immunologist Carolyn M. Kwiat, M.D. Joins ENT and Allergy Associates, LLP Bay Ridge West Office", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/veteran-allergist-immunologist-carolyn-m-142800729.html", "providerPublishTime": 1736432880, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/lRefVkySlq_lOA8Xh8qTug--~B/aD0yNzU7dz0yNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/64a2790c9832a87858e7bbd7c6ba503d", "width": 275, "height": 275, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/BD6WtctKoNTKGnuFywAL1g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/64a2790c9832a87858e7bbd7c6ba503d", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "5800292b-36cc-3bce-b51a-848c63af6f5c", "title": "Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-present-43rd-annual-120000424.html", "providerPublishTime": 1736337600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/L9m2jMPDcuACgBLxyupvJg--~B/aD03MzI7dz0yMTkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/20eebd9bf028a52d12c675881046f87b", "width": 2190, "height": 732, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/JS.WBMdrkJ3dt5ayjmIRVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/20eebd9bf028a52d12c675881046f87b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA"]}, {"uuid": "e991ac0e-b262-3236-8f5d-5e0d5daeed1d", "title": "Parallel ENT & Allergy adds Allergy & Asthma Associates of Michigan as a Parallel supported practice", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/parallel-ent-allergy-adds-allergy-155800539.html", "providerPublishTime": 1736265480, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MYGhBkOsMH9X9IhA72JuAw--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/770a98b050e625589559a6fb26c6a4b6", "width": 400, "height": 98, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/TPcTGTP.FUFdVMDnWOn.kw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/770a98b050e625589559a6fb26c6a4b6", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "c48ea932-7f2d-374c-aef6-77cd2bb9baf0", "title": "Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-moves-7-144300706.html", "providerPublishTime": 1734964980, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n4.AbgyuCxTPgpWcYEizKw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA", "NBIX"]}, {"uuid": "8d256682-19be-36a2-b138-8deaaf554b5d", "title": "Enanta Pharmaceuticals to Appeal Court Ruling on Patent Infringement Case Against Pfizer", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-appeal-court-ruling-125606599.html", "providerPublishTime": 1735044966, "type": "STORY", "relatedTickers": ["ENTA", "PFE"]}, {"uuid": "718758e6-0cea-3ef1-9390-7198ee4388cf", "title": "HC Wainwright Adjusts Price Target on Enanta Pharmaceuticals to $18 From $27, Maintains Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/hc-wainwright-adjusts-price-target-124154646.html", "providerPublishTime": 1735044114, "type": "STORY", "relatedTickers": ["ENTA"]}, {"uuid": "c8c956fc-1890-3486-b4d8-5c3e8a560611", "title": "Enanta Pharmaceuticals to Appeal Ruling Related to \u2018953 Patent Infringement Lawsuit", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-appeal-ruling-related-120000266.html", "providerPublishTime": 1735041600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fEPUhprdfnQV9a0U3lWN1A--~B/aD03MzI7dz0yMTkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/251da0d7ccfdf7cfc501f7f09a198d5a", "width": 2190, "height": 732, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/sCCN9SACQEoAjWlgjxdwWg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/251da0d7ccfdf7cfc501f7f09a198d5a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA"]}, {"uuid": "00309913-94a2-37ed-a14d-e3f09ecb449d", "title": "Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-reports-q4-221004778.html", "providerPublishTime": 1732572604, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 900, "height": 602, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HGBb_w3iAqceoCyVMucmoA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA"]}, {"uuid": "e46295b5-0d5f-3a38-999e-72fb52df62c7", "title": "Sector Update: Health Care Stocks Mixed Tuesday Afternoon", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-174744949.html", "providerPublishTime": 1735062464, "type": "STORY", "relatedTickers": ["ENTA", "PFE"]}, {"uuid": "5d3860b1-7182-329b-bcf8-c33e7b493a76", "title": "Top Midday Decliners", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/top-midday-decliners-173812910.html", "providerPublishTime": 1735061892, "type": "STORY", "relatedTickers": ["ENTA", "LEGN", "DSX-WS"]}, {"uuid": "c02d8bf4-8f69-3112-8526-fca4a640a795", "title": "Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/enanta-pharma-reports-positive-phase-153214711.html", "providerPublishTime": 1733758334, "type": "STORY", "relatedTickers": ["ENTA"]}, {"uuid": "6ef2c32e-6e3f-3d20-bf59-5a8a5e71e46b", "title": "Enanta Pharmaceuticals\u2019 Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-reduced-reporting-potential-060024790.html", "providerPublishTime": 1732860024, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/wwGxyfvBpmOeE73bj3.ufQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA"]}, {"uuid": "c9ee2c7a-5155-3ef5-bd91-915c74ea7545", "title": "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-210100464.html", "providerPublishTime": 1732568460, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/tWucMY.rWvIL5ieiYgNLfA--~B/aD03MzI7dz0yMTkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c066593f686a1f27e70baf78aea6462a", "width": 2190, "height": 732, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Hk8MO02qXzl8Blcg6kc6Ag--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c066593f686a1f27e70baf78aea6462a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA"]}, {"uuid": "db1989e1-3f90-3380-88a6-ec35b7f6f1f7", "title": "Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-announces-positive-topline-113000286.html", "providerPublishTime": 1733743800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/rbfaFpZVEXeQ6zSOYvPFjg--~B/aD03MzI7dz0yMTkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e100d2a51b79475e8239f419043a0e9f", "width": 2190, "height": 732, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/W11thnt3Qz1D_bi9LitJ.Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e100d2a51b79475e8239f419043a0e9f", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ENTA"]}, {"uuid": "1e230bc2-745f-3796-9000-ce869d3f97dc", "title": "Enanta Pharmaceuticals Fiscal Q4 Net Loss Widens, Revenue Declines", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/enanta-pharmaceuticals-fiscal-q4-net-222623071.html", "providerPublishTime": 1732573583, "type": "STORY", "relatedTickers": ["ENTA"]}, {"uuid": "75253acb-301c-3066-88ca-93f9d4c220bf", "title": "Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $14 From $16, Maintains Perform Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/oppenheimer-adjusts-enanta-pharmaceuticals-price-132945412.html", "providerPublishTime": 1732714185, "type": "STORY", "relatedTickers": ["ENTA"]}]